Article Text

Download PDFPDF
Metastatic chordoma with pancreatic disease and response to imatinib
  1. Eleanor V Klejnow1,
  2. Katie Hoban2,
  3. Ioanna Nixon3 and
  4. Thomas Robert Elswood4
  1. 1Department of Paediatric Haematology and Oncology, Queen Elizabeth University Hospital, Glasgow, UK
  2. 2Department of Orthopaedics, Queen Elizabeth University Hospital Campus, Glasgow, UK
  3. 3Department of Clinical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK
  4. 4Department of Radiology, NHS Greater Glasgow and Clyde, Glasgow, UK
  1. Correspondence to Dr Eleanor V Klejnow; eklejnow{at}gmail.com

Abstract

A 45-year-old woman presented with a left-sided neck swelling following treatment a year prior for cervical spine chordoma. She had initially been managed surgically with a cervical vertebrectomy and a course of proton beam therapy. Although there had been a degree of residual tissue, her disease remained stable radiologically and clinically. Repeat MRI demonstrated an increasing left paravertebral mass and a head of pancreas metastasis, which shared pathological characteristics with chordoma. Given the advanced metastatic nature of her disease, imatinib was offered with a palliative intent. While waiting for treatment she developed a spinal cord compression, managed with radiotherapy. She commenced imatinib and her disease remained stable for 9 months before progressing clinically and radiologically. This case demonstrates an unusual pattern of metastatic chordoma and provides further rationale for imatinib in such patients.

  • cancer intervention
  • malignant disease and immunosuppression
  • oncology
  • pharmacology and therapeutics
  • tyrosine kinase inhibitor

Statistics from Altmetric.com

Footnotes

  • Contributors IN proposed the case report and supervised the project. EVK wrote the report with contributions from KH. IN and EVK finalised the manuscript. TRE assisted in sourcing appropriate imaging.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.